Swedencare AB (publ)

Swedencare's capital structure is characterized by a market cap of 4.24 billion SEK and a price-to-book ratio of 0.64, indicating that the company's market value is below its book value. The company's liquidity position is assessed as medium, with a current ratio of 2.64, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's net cash position is negative after subtracting total debt, which may pose a liquidity risk. In terms of profitability, Swedencare's return on equity (ROE) is 0.83%, and its return on assets (ROA) is 0.58%, both of which are below the industry median for pharmaceutical companies. The company's gross profit margin is 32.47%, and its operating margin is 5.22%, which are also below the industry average. These metrics suggest that the company is not generating returns as efficiently as its peers. Swedencare's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's revenue is entirely derived from its pharmaceutical operations, and there is no indication of significant international exposure. This concentration may increase the company's vulnerability to market-specific risks. The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The company's operating cash flow is 326.8 million SEK, and its free cash flow is 274.9 million SEK, indicating that it generates positive cash from operations. However, the company's capital expenditure is negative, suggesting that it is not investing in new assets or expansion. Swedencare's risk profile is moderate, with a low dilution risk and a medium liquidity risk. The company's debt-to-equity ratio is 0.27, indicating a relatively conservative capital structure. However, the negative net cash position after subtracting total debt may require the company to seek additional financing, which could lead to dilution. The company has not disclosed any recent events or filings that would significantly impact its risk profile. Analyst estimates for Swedencare are generally positive, with a mean price target of 49.00 SEK and a median price target of 49.00 SEK. The mean recommendation is 2.00, indicating a "buy" rating, with one strong-buy, two buy, and one hold recommendation. These estimates suggest that analysts have a favorable outlook on the company's future performance.